1. Home
  2. Research
  3. Research Groups
  4. Neurodegenerative diseases: therapy development

Neurodegenerative diseases: therapy development

Search for publications

Only original articles, editorials, guidelines.

  • Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R.

    Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

    FRONTIERS IN NEUROSCIENCE . 10: 406-406. Number of citations: 64

    [doi:10.3389/fnins.2016.00406]

  • Palomo-Garo C, Gómez-Gálvez Y, García C, Fernández-Ruiz J.

    Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

    PHARMACOLOGICAL RESEARCH . 110: 181-192. Number of citations: 17

    [doi:10.1016/j.phrs.2016.04.004]

  • Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR.

    Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.

    PHARMACOLOGICAL RESEARCH . 110: 205-215. Number of citations: 17

    [doi:10.1016/j.phrs.2016.03.021]

  • Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.

    Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

    JOURNAL OF MEDICINAL CHEMISTRY . 59(14): 6753-6771. Number of citations: 23

    [doi:10.1021/acs.jmedchem.6b00397]

  • Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

    VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

    SCIENTIFIC REPORTS . 6: 29789-29789. Number of citations: 44

    [doi:10.1038/srep29789]

  • López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

    JOURNAL OF NEUROLOGY . 263(7): 1390-1400. Number of citations: 69

    [doi:10.1007/s00415-016-8145-9]

  • García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J.

    Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

    BRITISH JOURNAL OF PHARMACOLOGY . 173(13, SI): 2069-2079. Number of citations: 42

    [doi:10.1111/bph.13215]

  • Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA.

    Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 112: 66-80. Number of citations: 18

    [doi:10.1016/j.ejmech.2016.02.005]

  • Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J.

    Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.

    Pharmacology research & perspectives . 4(2): . Number of citations: 10

    [doi:10.1002/prp2.220]

  • Morales P, Whyte LS, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N.

    Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.

    JOURNAL OF MEDICINAL CHEMISTRY . 59(5): 1840-1853. Number of citations: 8

    [doi:10.1021/acs.jmedchem.5b01331]

  • Del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E.

    The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-? and CB2 pathways.

    SCIENTIFIC REPORTS . 6: 21703-21703. Number of citations: 52

    [doi:10.1038/srep21703]

  • Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García C.

    Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY . 64: 200-208. Number of citations: 105

    [doi:10.1016/j.pnpbp.2015.03.017]

  • de Salas-Quiroga A, Díaz-Alonso J, García-Rincón D, Remmers F, Vega D, Gómez-Cañas M, Lutz B, Guzmán M, Galve-Roperh I.

    Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 112(44): 13693-13698. Number of citations: 76

    [doi:10.1073/pnas.1514962112]

  • Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.

    The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Delta(9)-tetrahydrocannabinol acting through CB1 receptors

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 4(6): 505-511. Number of citations: 20

    [doi:10.1016/j.msard.2015.08.001]

  • Erdozain AM, Rubio M, Meana JJ, Fernández-Ruiz J, Callado LF.

    Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects

    JOURNAL OF PSYCHOPHARMACOLOGY . 29(11): 1137-1145. Number of citations: 10

    [doi:10.1177/0269881115599388]

  • Fernandez-Ruiz, Javier, Moro, Maria A., Martinez-Orgado, Jose.

    Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

    Neurotherapeutics . 12(4): 793-806. Number of citations: 81

    [doi:10.1007/s13311-015-0381-7]

  • Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos R, Pinna GA, Fernández-Ruiz J, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G.

    Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 101: 651-667. Number of citations: 11

    [doi:10.1016/j.ejmech.2015.06.057]

  • Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernández-Ruiz J, Alexander SP, Callado LF.

    The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects

    ADDICTION BIOLOGY . 20(4): 773-783. Number of citations: 23

    [doi:10.1111/adb.12160]